Early Data Convinces Some Oncologists to Treat ROS1-Positive NSCLC Patients with Xalkori | GenomeWeb

This article has been updated to correct the name of the Phase I extension trial to Study 1001. Originally published June 3.

CHICAGO – A small subset of non-small cell lung cancer patients with tumors that have rearrangements in the ROS1 gene have responded so well to Pfizer's Xalkori (crizotinib) in clinical trials that some academic medical oncologists are already incorporating screening for this molecular marker into clinical practice.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: weighting scheme increases GWAS power, and more.

Marc Tessier-Lavigne is to be the next president of Stanford University.

Walgreens has given Theranos 30 days to fix its lab issues, the Wall Street Journal reports.

Journals and research funding agencies pledge to enable the sharing of Zika virus research.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.